文献速递前列腺癌泌尿系感染

人类微生物组在前列腺癌中的作用:从诊断到治疗的系统综述

The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-11-18

该研究遵循PRISMA指南系统检索了截至2024年4月的810条记录,最终纳入42项研究,评估微生物组在前列腺癌诊断、预后和治疗反应中的作用。结果显示不同微生物谱可区分前列腺癌与对照,特定菌群与炎症、去势抵抗进展及治疗耐药相关。标准化微生物谱分析和微生物组调节策略可能有助于个体化管理。

要点

  • 生殖支原体和葡萄球菌属在前列腺肿瘤中富集并与炎症相关。
  • 肠道β变形菌富集预测更早去势抵抗进展,ADT诱导菌群失调加速耐药。
  • 放射治疗耗竭拟杆菌与直肠炎相关,免疫治疗应答者阿克曼菌丰度更高。

核心结论

  • 微生物组通过组织驻留和肠道来源的直接与间接机制影响前列腺癌检测、侵袭性和治疗疗效。
  • 标准化微生物谱分析和微生物组调节策略(如ADT期间益生菌)可能实现个体化管理。
  • 需要前瞻性试验验证因果关系并将微生物生物标志物转化为临床实践。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索PubMed、Embase和Cochrane Central Register of Controlled Trials截至2024年4月。
  • PROSPERO注册号CRD42024534899,纳入调查微生物在前列腺癌诊断、预后或治疗反应中作用的对照和观察性研究。
  • 从810条筛选记录中纳入42项研究,使用QUIPS工具进行数据提取和质量评估。

主要发现

  • 生殖支原体和葡萄球菌属在前列腺肿瘤中分别富集3.1倍和2.7倍,并与炎症相关(IL-6: r=0.38, p=0.002)。
  • 尿液微生物群显示诊断潜力(敏感性58-82%),但采样方法影响变异性。
  • 肠道β变形菌富集预测更早去势抵抗进展(5.2个月;HR 1.8, 95%CI 1.3-2.5),ADT诱导菌群失调(如克雷伯菌过度生长)加速耐药(风险2.1倍)。
  • 放射治疗耗竭拟杆菌(与直肠炎相关;OR 3.1),免疫治疗应答者阿克曼菌丰度更高。
  • 微生物雄激素合成和内毒素产生是耐药机制。

关键数值与推荐

  • 诊断敏感性58-82%(尿液微生物群)。
  • 生殖支原体富集3.1倍,葡萄球菌属富集2.7倍(前列腺肿瘤 vs 对照)。
  • IL-6与微生物相关:r=0.38, p=0.002。
  • β变形菌预测去势抵抗进展:5.2个月;HR 1.8, 95%CI 1.3-2.5。
  • ADT诱导菌群失调加速耐药风险2.1倍;放疗耗竭拟杆菌与直肠炎OR 3.1。

临床怎么用

  • 微生物谱可能辅助前列腺癌诊断和预后分层,但需标准化采样方法。
  • ADT期间可考虑微生物组调节策略(如益生菌)以延缓耐药。
  • 免疫治疗前评估阿克曼菌丰度可能预测应答。

局限性

  • 纳入研究多为观察性设计,无法确立因果关系。
  • 采样方法和微生物谱分析缺乏标准化导致变异性。
  • 需要前瞻性试验验证微生物生物标志物的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PC) heterogeneity and treatment resistance remain major clinical challenges, with emerging evidence implicating the microbiome as a key modulator of disease pathogenesis. While microbial dysbiosis has been linked to PC diagnosis, progression, and therapeutic outcomes, the mechanisms underlying these associations are poorly understood. This review synthesizes current evidence on the diagnostic, prognostic, and therapeutic potential of the microbiome in PC. METHODS: A systematic search of PubMed, Embase, and Cochrane Central Register of Controlled Trials (through April 2024) was conducted following PRISMA guidelines (PROSPERO: CRD42024534899). Controlled and observational studies investigating microbial roles in PC diagnosis (e.g., ISUP grading group), prognosis, or treatment response were included. Data extraction and quality assessment used the QUIPS tool. From 810 screened records, 42 studies met inclusion criteria. RESULTS: Distinct microbial profiles differentiated PC from controls, with Mycoplasma genitalium and Staphylococcus spp. enriched in prostate tumors (3.1- and 2.7-fold, respectively) and correlated with inflammation (IL-6: r = 0.38, p = 0.002). Urinary microbiota showed diagnostic potential (sensitivity: 58-82%), though sampling methods influenced variability. Prognostically, Betaproteobacteria gut enrichment predicted earlier castration-resistant progression (5.2 months; HR 1.8, 95% CI 1.3-2.5), while ADT-induced dysbiosis (e.g., Klebsiella overgrowth) accelerated resistance (2.1-fold risk). Therapies altered microbial ecology: radiotherapy depleted Bacteroides (linked to proctitis; OR 3.1), and immunotherapy responders harbored higher Akkermansia muciniphila. Microbial androgen synthesis and endotoxin production emerged as resistance mechanisms. CONCLUSIONS: The microbiome influences PC detection, aggressiveness, and treatment efficacy through direct (tissue-resident) and indirect (gut-derived) mechanisms. Standardized profiling and microbiome-modulating strategies (e.g., probiotics during ADT) may personalize management. Prospective trials are needed to validate causality and translate microbial biomarkers into clinical practice.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Distante A, Garino D, Cerrato C, et al. The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment. Prostate Cancer Prostatic Dis. 2025. PMID: 41254344. doi:10.1038/s41391-025-01028-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。